Identification and properties of plasma membrane azole efflux pumps from the pathogenic fungi Cryptococcus gattii and Cryptococcus neoformans

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 5, 2014, Pages 1396-1407

  Basso, Luiz R ^a,b   Gast, Charles E ^a   Bruzual, Igor ^a   Wong, Brian ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Azole resistance; C. gattii; C. neoformans

Indexed keywords

AMPHOTERICIN; AMPHOTERICIN B; COMPLEMENTARY DNA; FLUCONAZOLE; ITRACONAZOLE; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; ORTHOVANADIC ACID; POSACONAZOLE; PYRROLE; VORICONAZOLE; ANTIFUNGAL AGENT; CARRIER PROTEIN; PYRROLE DERIVATIVE;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CELL FRACTIONATION; CELL SURFACE; CONTROLLED STUDY; CRYPTOCOCCUS GATTII; CRYPTOCOCCUS NEOFORMANS; FLUORESCENCE MICROSCOPY; FUNGAL CELL; FUNGAL GENOME; GENE EXPRESSION; HETEROLOGOUS EXPRESSION; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR CLONING; NONHUMAN; PLASMA MEMBRANE AZOLE EFFLUX PUMP; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SACCHAROMYCES CEREVISIAE; TRANSMISSION ELECTRON MICROSCOPY; ACTIVE TRANSPORT; CRYPTOCOCCOSIS; DNA SEQUENCE; DRUG EFFECTS; ENZYMOLOGY; GENE EXPRESSION PROFILING; GENETICS; HUMAN; ISOLATION AND PURIFICATION; ISOTOPE LABELING; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; UNITED STATES;

ANTIFUNGAL AGENTS; AZOLES; BIOLOGICAL TRANSPORT, ACTIVE; CLONING, MOLECULAR; CRYPTOCOCCOSIS; CRYPTOCOCCUS GATTII; CRYPTOCOCCUS NEOFORMANS; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; ISOTOPE LABELING; MEMBRANE TRANSPORT PROTEINS; MICROBIAL SENSITIVITY TESTS; NORTHWESTERN UNITED STATES; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SACCHAROMYCES CEREVISIAE; SEQUENCE ANALYSIS, DNA;

EID: 84929753067     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku554     Document Type: Article

References (42)

1. Harris JR, Lockhart SR, Debess E et al. Cryptococcus gattii in the United States: clinical aspects of infection with an emerging pathogen. Clin Infect Dis 2011; 53: 1188-95.
2. Sorrell TC. Cryptococcus neoformans variety gattii. Med Mycol 2001; 39:155-68.
3. Hoang LM, Maguire JA, Doyle P et al. Cryptococcus neoformans infections at Vancouver Hospital and Health Sciences Centre (1997-2002): epidemiology, microbiology and histopathology. J Med Microbiol 2004; 53:935-40.
4. Upton A, Fraser JA, Kidd SE et al. First contemporary case of human infection with Cryptococcus gattii in Puget Sound: evidence for spread of the Vancouver Island outbreak. J Clin Microbiol 2007; 45: 3086-8.
5. Lockhart SR, Iqbal N, Harris JR et al. Cryptococcus gattii in the United States: genotypic diversity of human and veterinary isolates. PLoS One 2013; 8: e74737.
6. Galanis E, Macdougall L. Epidemiology of Cryptococcus gattii, British Columbia, Canada, 1999-2007. Emerg Infect Dis 2010; 16: 251-7.
7. Speed B, Dunt D. Clinical and host differences between infections with the two varieties of Cryptococcus neoformans. Clin Infect Dis 1995; 21:28-34; discussion 35-6.
8. Mitchell DH, Sorrell TC, Allworth AM et al. Cryptococcal disease of the CNS in immunocompetent hosts: influence of cryptococcal variety on clinical manifestations and outcome. Clin Infect Dis 1995; 20: 611-6.
9. Gomez-Lopez A, Zaragoza O, Dos Anjos Martins M et al. In vitro susceptibility of Cryptococcus gattii clinical isolates. Clin Microbiol Infect 2008; 14:727-30.
10. Gast CE, Basso LR Jr, Bruzual I et al. Azole resistance in Cryptococcus gattii from the Pacific Northwest: Investigation of the role of ERG11. Antimicrob Agents Chemother 2013; 57: 5478-85.
11. Lockhart SR, Iqbal N, Bolden CB et al. Epidemiologic cutoff values for triazole drugs in Cryptococcus gattii: correlation of molecular type and in vitro susceptibility. Diagn Microbiol Infect Dis 2012; 73: 144-8.
12. Iqbal N, DeBess EE, Wohrle R et al. Correlation of genotype and in vitro susceptibilities of Cryptococcus gattii strains from the Pacific Northwest of the United States. J Clin Microbiol 2010; 48: 539-44.
13. Cowen LE, Sanglard D, Calabrese D et al. Evolution of drug resistance in experimental populations of Candida albicans. J Bacteriol 2000; 182:1515-22.
14. Selmecki A, Forche A, Berman J. Aneuploidy and isochromosome formation in drug-resistant Candida albicans. Science 2006; 313: 367-70.
15. Selmecki A, Gerami-Nejad M, Paulson C et al. An isochromosome confers drug resistance in vivo by amplification of two genes, ERG11 and TAC1. Mol Microbiol 2008; 68: 624-41.
16. Selmecki AM, Dulmage K, Cowen LE et al. Acquisition of aneuploidy provides increased fitness during the evolution of antifungal drug resistance. PLoS Genet 2009; 5: e1000705.
17. Venkateswarlu K, Taylor M, Manning NJ et al. Fluconazole tolerance in clinical isolates of Cryptococcus neoformans. Antimicrob Agents Chemother 1997; 41: 748-51.
18. Sanglard D, Ischer F, Koymans L et al. Amino acid substitutions in the cytochrome P-450 lanosterol 14a-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents. Antimicrob Agents Chemother 1998; 42:241-53.
19. Marichal P, Koymans L, Willemsens S et al. Contribution of mutations in the cytochrome P450 14a-demethylase (Erg11p, Cyp51p) to azole resistance in Candida albicans. Microbiology 1999; 145: 2701-13.
20. Ji H, Zhang W, Zhou Y et al. A three-dimensional model of lanosterol 14a-demethylase of Candida albicans and its interaction with azole antifungals. J Med Chem 2000; 43: 2493-505.
21. Coste A, Selmecki A, Forche A et al. Genotypic evolution of azole resistance mechanisms in sequential Candida albicans isolates. Eukaryot Cell 2007; 6: 1889-904.
22. Sheng C, Miao Z, Ji H et al. Three-dimensional model of lanosterol 14a-demethylase from Cryptococcus neoformans: active-site characterization and insights into azole binding. Antimicrob Agents Chemother 2009; 53: 3487-95.
23. Basso LR Jr, Gast CE, Mao Y et al. Fluconazole transport into Candida albicans secretory vesicles by the membrane proteins Cdr1p, Cdr2p, and Mdr1p. Eukaryot Cell 2010; 9: 960-70.
24. White TC. Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob Agents Chemother 1997; 41: 1482-7.
25. Prasad R, DeWergifosse P, Goffeau A et al. Molecular cloning and characterization of a novel gene of Candida albicans, CDR1, conferring multiple resistance to drugs and antifungals. Curr Genet 1995; 27: 320-9.
26. Sanglard D, Kuchler K, Ischer F et al. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob Agents Chemother 1995; 39:2378-86.
27. Sanglard D, Ischer F, Monod M et al. Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene. Microbiology 1997; 143: 405-16.
28. Thornewell SJ, Peery RB, Skatrud PL. Cloning and characterization of CneMDR1: a Cryptococcus neoformans gene encoding a protein related to multidrug resistance proteins. Gene 1997; 201: 21-9.
29. Posteraro B, Sanguinetti M, Sanglard D et al. Identification and characterization of a Cryptococcus neoformans ATP binding cassette (ABC) transporter-encoding gene, CnAFR1, involved in the resistance to fluconazole. Mol Microbiol 2003; 47: 357-71.
30. Sanguinetti M, Posteraro B, La Sorda M et al. Role of AFR1, an ABC transporter-encoding gene, in the in vivo response to fluconazole and virulence of Cryptococcus neoformans. Infect Immun 2006; 74: 1352-9.
31. Gaur M, Choudhury D, Prasad R. Complete inventory of ABC proteins in human pathogenic yeast, Candida albicans. J Mol Microbiol Biotechnol 2005; 9: 3-15.
32. Coste AT, Crittin J, Bauser C et al. Functional analysis of cis- and transacting elements of the Candida albicans CDR2 promoter with a novel promoter reporter system. Eukaryot Cell 2009; 8: 1250-67.
33. Orsi CF, Colombari B, Ardizzoni A et al. The ABC transporter-encoding gene AFR1 affects the resistance of Cryptococcus neoformans to microgliamediated antifungal activity by delaying phagosomal maturation. FEMS Yeast Res 2009; 9: 301-10.
34. Morschhauser J. Regulation of multidrug resistance in pathogenic fungi. Fungal Genet Biol 2010; 47: 94-106.
35. Manoharlal R, Gaur NA, Panwar SL et al. Transcriptional activation and increased mRNA stability contribute to overexpression of CDR1 in azoleresistant Candida albicans. Antimicrob Agents Chemother 2008; 52: 1481-92.
36. Lamping E, Monk BC, Niimi K et al. Characterization of three classes of membrane proteins involved in fungal azole resistance by functional hyperexpression in Saccharomyces cerevisiae. Eukaryot Cell 2007; 6: 1150-65.
37. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts-Third Edition:Approved Standard M27-A3. CLSI, Wayne, PA, USA, 2008.
38. Ruetz S, Gros P. Phosphatidylcholine translocase: a physiological role for the mdr2 gene. Cell 1994; 77: 1071-81.
39. Ruetz S, Gros P. Functional expression of P-glycoproteins in secretory vesicles. J Biol Chem 1994; 269: 12277-84.
40. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-54.
41. Cannon RD, Fischer FJ, Niimi K et al. Drug pumping mechanisms in Candida albicans. Nihon Ishinkin Gakkai Zasshi 1998; 39: 73-8.
42. Niimi M, Niimi K, Takano Y et al. Regulated overexpression of CDR1 in Candida albicans confers multidrug resistance. J Antimicrob Chemother 2004; 54: 999-1006.